CY1116873T1 - Πολυπεπτιδιο ace2 - Google Patents
Πολυπεπτιδιο ace2Info
- Publication number
- CY1116873T1 CY1116873T1 CY20151100955T CY151100955T CY1116873T1 CY 1116873 T1 CY1116873 T1 CY 1116873T1 CY 20151100955 T CY20151100955 T CY 20151100955T CY 151100955 T CY151100955 T CY 151100955T CY 1116873 T1 CY1116873 T1 CY 1116873T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ace2 polypeptide
- dimer
- ace2
- polypeptide
- life
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση αφορά ανασυνδυασμένο πολυπεπτίδιο ACE2, όπου το πολυπεπτίδιο ACE2 υφίσταται ως διμερές. Το διμερές σχηματίζεται ειδικότερα από γλυκοζυλιωμένα μονομερή και χρησιμοποιείται για την παρασκευή φαρμακευτικών προϊόντων με παρατεταμένο χρόνο ημιζωής.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0091307A AT505262A1 (de) | 2007-06-12 | 2007-06-12 | Rekombinantes ace2 polypeptid |
EP08450052A EP2108695A1 (de) | 2008-04-08 | 2008-04-08 | Ace2 Polypeptid |
EP08756821.8A EP2155871B1 (de) | 2007-06-12 | 2008-06-12 | Ace2 polypeptid |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116873T1 true CY1116873T1 (el) | 2017-04-05 |
Family
ID=39720296
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100955T CY1116873T1 (el) | 2007-06-12 | 2015-10-26 | Πολυπεπτιδιο ace2 |
CY20181100549T CY1120426T1 (el) | 2007-06-12 | 2018-05-23 | Πολυπεπτιδιο ace2 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100549T CY1120426T1 (el) | 2007-06-12 | 2018-05-23 | Πολυπεπτιδιο ace2 |
Country Status (35)
Country | Link |
---|---|
US (3) | US8586319B2 (el) |
EP (3) | EP3375872A1 (el) |
JP (1) | JP5731193B2 (el) |
KR (2) | KR20160054045A (el) |
CN (2) | CN101796183A (el) |
AT (1) | AT505262A1 (el) |
AU (1) | AU2008261591B2 (el) |
BR (1) | BRPI0813942B8 (el) |
CA (1) | CA2692854C (el) |
CO (1) | CO6270265A2 (el) |
CR (1) | CR11213A (el) |
CY (2) | CY1116873T1 (el) |
DK (2) | DK2543724T3 (el) |
DO (1) | DOP2009000282A (el) |
EA (1) | EA027399B1 (el) |
EG (1) | EG27095A (el) |
ES (2) | ES2670938T3 (el) |
HK (2) | HK1255493A1 (el) |
HR (2) | HRP20151120T1 (el) |
HU (2) | HUE037877T2 (el) |
IL (1) | IL202653B (el) |
LT (1) | LT2543724T (el) |
MA (1) | MA31472B1 (el) |
MX (1) | MX2009013472A (el) |
MY (1) | MY180672A (el) |
NO (1) | NO2543724T3 (el) |
NZ (1) | NZ581704A (el) |
PL (2) | PL2155871T3 (el) |
PT (2) | PT2543724T (el) |
RS (2) | RS54340B1 (el) |
SI (2) | SI2543724T1 (el) |
TR (1) | TR201808117T4 (el) |
UA (1) | UA106869C2 (el) |
WO (1) | WO2008151347A1 (el) |
ZA (1) | ZA200908751B (el) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
EP2077119A1 (de) * | 2007-12-21 | 2009-07-08 | Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. | Behandlung von Fibrosen und Lebererkrankungen |
AT506632A1 (de) * | 2008-04-09 | 2009-10-15 | Apeiron Biolog Forschungs Und | Behandlung von tumorerkrankungen |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
CA2876099A1 (en) | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | Method for producing monomeric and multimeric molecules and uses thereof |
BR122020018510B1 (pt) | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
ES2732282T3 (es) * | 2013-01-14 | 2019-11-21 | Apeiron Biologics Ag | Polipéptidos de ECA2 modificados |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
AU2017296352A1 (en) | 2016-07-11 | 2019-02-21 | Opko Biologics Ltd. | Long-acting coagulation factor VII and methods of producing same |
US11518788B2 (en) * | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
EP3884957A1 (en) | 2020-03-26 | 2021-09-29 | The University of British Columbia | Methods for treatment of virus and methods for screening of anti-virus reagent using organoids |
WO2021217120A2 (en) * | 2020-04-24 | 2021-10-28 | Administrators Of The Tulane Educational Fund | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor |
CN113667016A (zh) * | 2020-05-15 | 2021-11-19 | 普米斯生物技术(珠海)有限公司 | 一种构建冠状病毒抗体的平台 |
WO2021247675A1 (en) | 2020-06-02 | 2021-12-09 | Ngm Biopharmaceuticals, Inc. | Coronavirus-binding agents and uses thereof |
DE102020207224A1 (de) | 2020-06-09 | 2021-12-09 | Christoph Karle | Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon |
EP4171603A1 (en) * | 2020-06-25 | 2023-05-03 | Gliknik Inc. | Ace2-fc fusion proteins and methods of use |
WO2022008642A1 (en) | 2020-07-08 | 2022-01-13 | Apeiron Biologics Ag | Treatment of sars-cov-2 infection with a combination of targets |
US20220025071A1 (en) * | 2020-07-10 | 2022-01-27 | Biomolecular Holdings Llc | Tetrahedral antibodies |
CN116710560A (zh) * | 2020-08-21 | 2023-09-05 | 西湖大学 | 工程化ace2寡聚物及其用途 |
CN112280764A (zh) * | 2020-11-18 | 2021-01-29 | 通用生物系统(安徽)有限公司 | 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法 |
EP4011387A1 (en) | 2020-12-11 | 2022-06-15 | IMBA-Institut für Molekulare Biotechnologie GmbH | Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2 |
WO2022159433A1 (en) | 2021-01-20 | 2022-07-28 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
WO2022207918A1 (en) | 2021-04-02 | 2022-10-06 | Apeiron Biologics Ag | COVID-19 Therapy |
WO2023023424A1 (en) * | 2021-08-19 | 2023-02-23 | Phenom Pharmaceuticals, Inc. | Compositions and methods for treatment of sars cov-2 |
CN113897346A (zh) * | 2021-09-16 | 2022-01-07 | 四川大学 | 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
US6610497B1 (en) | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
US6194556B1 (en) * | 1997-12-11 | 2001-02-27 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor |
PT2332582E (pt) * | 2002-06-19 | 2014-01-28 | Apeiron Biologics Ag | Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão |
WO2004023270A2 (en) | 2002-09-09 | 2004-03-18 | Millenium Pharmaceuticals, Inc. | Crystal structure of angiotensin-converting enzyme-related carboxypeptidase |
EP1723962A1 (en) * | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
AT504443B1 (de) * | 2006-10-19 | 2008-11-15 | Apeiron Biolog Forschungs Und | Verfahren zur bestimmung der aktivität von ace2 |
AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
EP2108695A1 (de) * | 2008-04-08 | 2009-10-14 | Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. | Ace2 Polypeptid |
AT506258A1 (de) * | 2007-12-18 | 2009-07-15 | Apeiron Biolog Forschungs Und | Behandlung inflammatorischer krankheiten |
AT506632A1 (de) * | 2008-04-09 | 2009-10-15 | Apeiron Biolog Forschungs Und | Behandlung von tumorerkrankungen |
-
2007
- 2007-06-12 AT AT0091307A patent/AT505262A1/de not_active Application Discontinuation
-
2008
- 2008-06-12 EP EP18161541.0A patent/EP3375872A1/de not_active Withdrawn
- 2008-06-12 MX MX2009013472A patent/MX2009013472A/es active IP Right Grant
- 2008-06-12 BR BRPI0813942A patent/BRPI0813942B8/pt active IP Right Grant
- 2008-06-12 CN CN200880100650A patent/CN101796183A/zh active Pending
- 2008-06-12 UA UAA200912888A patent/UA106869C2/uk unknown
- 2008-06-12 KR KR1020167011786A patent/KR20160054045A/ko not_active Application Discontinuation
- 2008-06-12 EP EP12165189.7A patent/EP2543724B1/de active Active
- 2008-06-12 PL PL08756821T patent/PL2155871T3/pl unknown
- 2008-06-12 CA CA2692854A patent/CA2692854C/en active Active
- 2008-06-12 PT PT121651897T patent/PT2543724T/pt unknown
- 2008-06-12 ES ES12165189.7T patent/ES2670938T3/es active Active
- 2008-06-12 RS RS20150709A patent/RS54340B1/en unknown
- 2008-06-12 SI SI200831961T patent/SI2543724T1/en unknown
- 2008-06-12 TR TR2018/08117T patent/TR201808117T4/tr unknown
- 2008-06-12 ES ES08756821.8T patent/ES2550390T3/es active Active
- 2008-06-12 HU HUE12165189A patent/HUE037877T2/hu unknown
- 2008-06-12 WO PCT/AT2008/000211 patent/WO2008151347A1/de active Application Filing
- 2008-06-12 NO NO12165189A patent/NO2543724T3/no unknown
- 2008-06-12 CN CN201410412672.3A patent/CN104450654A/zh active Pending
- 2008-06-12 JP JP2010511445A patent/JP5731193B2/ja active Active
- 2008-06-12 MY MYPI20095316A patent/MY180672A/en unknown
- 2008-06-12 NZ NZ581704A patent/NZ581704A/en unknown
- 2008-06-12 AU AU2008261591A patent/AU2008261591B2/en active Active
- 2008-06-12 SI SI200831514T patent/SI2155871T1/sl unknown
- 2008-06-12 US US12/664,641 patent/US8586319B2/en active Active
- 2008-06-12 PL PL12165189T patent/PL2543724T3/pl unknown
- 2008-06-12 DK DK12165189.7T patent/DK2543724T3/en active
- 2008-06-12 HU HUE08756821A patent/HUE028012T2/en unknown
- 2008-06-12 KR KR1020097027569A patent/KR101682240B1/ko active IP Right Grant
- 2008-06-12 DK DK08756821.8T patent/DK2155871T3/en active
- 2008-06-12 PT PT87568218T patent/PT2155871E/pt unknown
- 2008-06-12 LT LTEP12165189.7T patent/LT2543724T/lt unknown
- 2008-06-12 RS RS20180677A patent/RS57292B1/sr unknown
- 2008-06-12 EA EA201000002A patent/EA027399B1/ru unknown
- 2008-06-12 EP EP08756821.8A patent/EP2155871B1/de active Active
-
2009
- 2009-01-01 ZA ZA200908751A patent/ZA200908751B/xx unknown
- 2009-12-10 IL IL202653A patent/IL202653B/en active IP Right Grant
- 2009-12-10 EG EG2009121812A patent/EG27095A/xx active
- 2009-12-11 DO DO2009000282A patent/DOP2009000282A/es unknown
- 2009-12-30 MA MA32464A patent/MA31472B1/fr unknown
-
2010
- 2010-01-08 CO CO10001879A patent/CO6270265A2/es not_active Application Discontinuation
- 2010-01-12 CR CR11213A patent/CR11213A/es unknown
- 2010-04-28 HK HK18114676.2A patent/HK1255493A1/zh unknown
- 2010-04-28 HK HK10104145.4A patent/HK1136602A1/xx unknown
-
2013
- 2013-09-13 US US14/026,887 patent/US20140099297A1/en not_active Abandoned
-
2015
- 2015-10-23 HR HRP20151120TT patent/HRP20151120T1/hr unknown
- 2015-10-26 CY CY20151100955T patent/CY1116873T1/el unknown
-
2017
- 2017-12-06 US US15/833,243 patent/US10716833B2/en active Active
-
2018
- 2018-05-23 CY CY20181100549T patent/CY1120426T1/el unknown
- 2018-05-30 HR HRP20180856TT patent/HRP20180856T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116873T1 (el) | Πολυπεπτιδιο ace2 | |
CY1120407T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
CY1121225T1 (el) | Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις | |
AU2017204797B2 (en) | Antibodies with modified isoelectric points | |
CY1117479T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
CL2013003090A1 (es) | Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso. | |
WO2012175222A8 (en) | AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES | |
CY1116064T1 (el) | Συστασεις αναστολεα ddp iv | |
CY1118875T1 (el) | Αντιδοτα αντιπηκτικων | |
WO2008145137A3 (en) | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering | |
CA2818990A1 (en) | Designed repeat proteins binding to serum albumin | |
EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
EP4269441A3 (en) | Il-15 and il-15ralpha sushi domain based on modulokines | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
UY31597A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
EA201171325A1 (ru) | Нуклеиновые кислоты, связывающиеся с гепсидином | |
MY160552A (en) | Low protein infant formula with increased essential amino acids | |
TR201900207T4 (tr) | Faktör VIII Formülasyonları | |
WO2014052451A3 (en) | Insulin analog dimers | |
BR112014011560A2 (pt) | complexos imunogênicos de carbômeros polianiônicos e polipeptídeos env, e métodos de fabricação e uso dos mesmos | |
CY1117300T1 (el) | Νεα ενισχυμενη συσκευασια με φυσαλιδες | |
AR082422A1 (es) | Composicion detergente liquida | |
DE602006017705D1 (de) | Zytotoxische ribonukleasevarianten | |
FR2897063B1 (fr) | Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications. | |
BR112013004294A2 (pt) | métodos e materiais para fornecimento de dentes com uma aparência branca. |